Conese M, Nykjaer A, Petersen C M, Cremona O, Pardi R, Andreasen P A, Gliemann J, Christensen E I, Blasi F
Dipartimento di Ricerca Biologica e Tecnologica, H.S. Raffaele Scientific Institute, Università di Milano, Italy.
J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. doi: 10.1083/jcb.131.6.1609.
The GPI-anchored urokinase plasminogen activator receptor (uPAR) does not internalize free urokinase (uPA). On the contrary, uPAR-bound complexes of uPA with its serpin inhibitors PAI-1 (plasminogen activator inhibitor type-1) or PN-1 (protease nexin-1) are readily internalized in several cell types. Here we address the question whether uPAR is internalized as well upon binding of uPA-serpin complexes. Both LB6 clone 19 cells, a mouse cell line transfected with the human uPAR cDNA, and the human U937 monocytic cell line, express in addition to uPAR also the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP/alpha 2-MR) which is required to internalize uPAR-bound uPA-PAI-1 and uPA-PN-1 complexes. Downregulation of cell surface uPAR molecules in U937 cells was detected by cytofluorimetric analysis after uPA-PAI-1 and uPA-PN-1 incubation for 30 min at 37 degrees C; this effect was blocked by preincubation with the ligand of LRP/alpha 2-MR, RAP (LRP/alpha 2-MR-associated protein), known to block the binding of the uPA complexes to LRP/alpha 2-. MR. Downregulation correlated in time with the intracellular appearance of uPAR as assessed by confocal microscopy and immuno-electron microscopy. After 30 min incubation with uPA-PAI-1 or uPA-PN-1 (but not with free uPA), confocal microscopy showed that uPAR staining in permeabilized LB6 clone 19 cells moved from a mostly surface associated to a largely perinuclear position. This effect was inhibited by the LRP/alpha 2-MR RAP. Perinuclear uPAR did not represent newly synthesized nor a preexisting intracellular pool of uPAR, since this fluorescence pattern was not modified by treatment with the protein synthesis inhibitor cycloheximide, and since in LB6 clone 19 cells all of uPAR was expressed on the cell surface. Immuno-electron microscopy confirmed the plasma membrane to intracellular translocation of uPAR, and its dependence on LRP/alpha 2-MR in LB6 clone 19 cells only after binding to the uPA-PAI-1 complex. After 30 min incubation at 37 degrees C with uPA-PAI-1, 93% of the specific immunogold particles were present in cytoplasmic vacuoles vs 17.6% in the case of DFP-uPA. We conclude therefore that in the process of uPA-serpin internalization, uPAR itself is internalized, and that internalization requires the LRP/alpha 2-MR.
糖基磷脂酰肌醇(GPI)锚定的尿激酶型纤溶酶原激活物受体(uPAR)不会内化游离的尿激酶(uPA)。相反,uPA与其丝氨酸蛋白酶抑制剂PAI-1(1型纤溶酶原激活物抑制剂)或PN-1(蛋白酶连接蛋白-1)结合形成的复合物在多种细胞类型中很容易被内化。在此,我们探讨uPA-丝氨酸蛋白酶抑制剂复合物结合后uPAR是否也会被内化的问题。LB6克隆19细胞是一种转染了人uPAR cDNA的小鼠细胞系,人U937单核细胞系除了表达uPAR外,还表达内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白(LRP/α2-MR),该蛋白是内化uPAR结合的uPA-PAI-1和uPA-PN-1复合物所必需的。在37℃下用uPA-PAI-1和uPA-PN-1孵育30分钟后,通过细胞荧光分析检测到U937细胞表面uPAR分子的下调;这种效应被与LRP/α2-MR的配体RAP(LRP/α2-MR相关蛋白)预孵育所阻断,已知RAP可阻断uPA复合物与LRP/α2-MR的结合。通过共聚焦显微镜和免疫电子显微镜评估,下调与uPAR在细胞内的出现时间相关。在用uPA-PAI-1或uPA-PN-1(但不是游离uPA)孵育30分钟后,共聚焦显微镜显示,通透的LB6克隆19细胞中的uPAR染色从主要与表面相关的位置转移到了大部分位于核周的位置。这种效应被LRP/α2-MR的RAP所抑制。核周的uPAR既不代表新合成的uPAR,也不代表预先存在的细胞内uPAR池,因为这种荧光模式不会因用蛋白质合成抑制剂环己酰亚胺处理而改变,并且因为在LB6克隆19细胞中所有的uPAR都表达在细胞表面。免疫电子显微镜证实,仅在与uPA-PAI-1复合物结合后,LB6克隆19细胞中uPAR从质膜向细胞内发生了转运,并且其转运依赖于LRP/α2-MR。在37℃下用uPA-PAI-1孵育30分钟后,93%的特异性免疫金颗粒存在于细胞质空泡中,而在DFP-uPA的情况下为17.6%。因此,我们得出结论,在uPA-丝氨酸蛋白酶抑制剂内化过程中,uPAR本身也会被内化,并且内化需要LRP/α2-MR。